Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of “Buy” by Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has earned an average recommendation of “Buy” from the five brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $78.50.

PCVX has been the topic of a number of research reports. Bank of America boosted their target price on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Needham & Company LLC boosted their target price on shares of Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Mizuho began coverage on shares of Vaxcyte in a research report on Thursday, December 7th. They issued a “buy” rating and a $69.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th.

Insider Activity at Vaxcyte

In related news, SVP Elvia Cowan sold 11,678 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $74.08, for a total transaction of $865,106.24. Following the transaction, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vaxcyte news, SVP Elvia Cowan sold 11,678 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $74.08, for a total transaction of $865,106.24. Following the completion of the sale, the senior vice president now owns 12,480 shares in the company, valued at approximately $924,518.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $63.93, for a total transaction of $106,571.31. Following the sale, the senior vice president now owns 20,710 shares of the company’s stock, valued at approximately $1,323,990.30. The disclosure for this sale can be found here. Insiders have sold 129,860 shares of company stock worth $8,720,633 in the last quarter. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Vaxcyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Vaxcyte by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after purchasing an additional 167,501 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Vaxcyte by 20.6% in the 3rd quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after acquiring an additional 300,189 shares in the last quarter. UBS Group AG grew its stake in shares of Vaxcyte by 62.2% in the 3rd quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after acquiring an additional 28,483 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Vaxcyte by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock worth $422,331,000 after acquiring an additional 47,872 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Vaxcyte by 67.9% in the 3rd quarter. Barclays PLC now owns 170,412 shares of the company’s stock worth $8,688,000 after acquiring an additional 68,904 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Down 0.3 %

Shares of Vaxcyte stock opened at $68.31 on Friday. Vaxcyte has a 1 year low of $34.11 and a 1 year high of $82.04. The firm has a market capitalization of $7.41 billion, a PE ratio of -16.54 and a beta of 0.91. The firm’s 50 day moving average is $71.21 and its 200 day moving average is $59.55.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period in the previous year, the company earned ($0.73) EPS. As a group, research analysts anticipate that Vaxcyte will post -4.18 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.